With the aim of growing its neurodegenerative diseases business, Zhejiang Jingxin Pharmaceutical has reached an agreement to acquire up to 5% stake in Israeli-based Pharma Two B.
The Chinese company will pay a purchase consideration of $5m to the target company, as part of the transaction.
Go deeper with GlobalData
The target company develops treatment for Parkinson's disease and cancer, while the acquirer company is a Chinese pharmaceutical company.
Israeli biopharmaceutical company BioLineRx has completed the acquisition of Agalimmune and its technology platform, with the aim of enhancing its position in the immuno-oncology space.
The UK-based target company, which develops anti-cancer immunotherapy products, has received $6m in purchase consideration for the transaction, including $3m in cash and the remaining in the acquirer company’s shares.
The target company is also entitled for future development and commercial milestone-based payments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
